Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid

被引：0
|
作者：
Coelho, T. [1 ]
Maia, L. [1 ]
Martins da Silva, A. [1 ]
Waddingtion-Cruz, M. [2 ]
Plante-Bordeneuve, V. [3 ]
Lozeron, P. [4 ]
Suhr, O. B. [5 ]
Campistol, J. [6 ]
Conceicao, I. M. [7 ]
Schmidt, H. [8 ]
Trigo, P. [9 ]
Packman, J. [10 ]
Grogan, D. R. [10 ]
机构：
[1] Hosp Santo Antonio, Dept Neurophysiol, Oporto, Portugal
[2] Univ Fed Rio de Janeiro, Univ Hosp, Neurol Serv, BR-21941 Rio De Janeiro, Brazil
[3] CHU Henri Mondor, Dept Neurol, F-94010 Creteil, France
[4] CHU Bicetre, Dept Neurol, Le Kremlin Bicetre, France
[5] Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden
[6] Hosp Clin Barcelona, Renal Transplant Unit, Barcelona, Spain
[7] Hosp Santa Maria, Dept Neurol, Lisbon, Portugal
[8] Univ Klinikum Munster, Munster, Germany
[9] FLENI, Buenos Aires, DF, Argentina
[10] FoldRx Pharmaceut Inc, Cambridge, MA USA
来源：
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2010年 / 17卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：75 / 76
页数：2
相关论文
共 50 条
  • [1] Tafamidis (Fx-1006A): A First-In-Class Disease-Modifying Therapy for Transthyretin Type Familial Amyloid Polyneuropathy
    Coelho, Teresa
    Maia, Luis
    da Silva, Ana Martins
    Waddington, Marcia
    Plante-Bordeneuve, Violane
    Lozeron, Pierre
    Suhr, Ole B.
    Campistol, Josep
    Conceicao, Isabel
    Schmidt, Hartmut
    Trigo, Pedro
    Packman, Jeff
    Grogan, Donna R.
    NEUROLOGY, 2010, 74 (09) : A286 - A286
  • [2] Sustainability of response to tafamidis, a disease-modifying therapy for transthyretin type familial amyloid polyneuropathy
    Coelho, T.
    Maia, L.
    Silva, A.
    Cruz, M. Waddington
    Plante-Bordeneuve, V.
    Suhr, O. B.
    Conceicao, I.
    Schmidt, H.
    Trigo, P.
    Packman, J.
    Grogan, D. R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 35 - 35
  • [3] Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy
    Park, Jonathan
    Egolum, Ugochukwu
    Parker, Shanea
    Andrews, Ebony
    Ombengi, David
    Ling, Hua
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (05) : 470 - 477
  • [4] A Comprehensive Evaluation of the Disease-Modifying Effects of Tafamidis in Patients with Transthyretin Type Familial Amyloid Polyneuropathy
    Coelho, Teresa
    Maia, Luis
    da Silva, Ana Martins
    Cruz, Marcia Waddington
    Plante-Bordeneuve, Violaine
    Lozeron, Pierre
    Suhr, Ole B.
    Campistol, Josep
    Conceicao, Isabel
    Schmidt, Hartmut
    Trigo, Pedro
    Packman, Jeff
    Grogan, Donna R.
    NEUROLOGY, 2011, 76 (09) : A111 - A111
  • [5] INFLUENCE OF BASELINE NEUROLOGIC SEVERITY ON DISEASE PROGRESSION AND THE ASSOCIATED DISEASE-MODIFYING EFFECTS OF TAFAMIDIS IN TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
    Amass, L.
    Li, H.
    Gundapaneni, B.
    Schwartz, J.
    Keohane, D.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 235 - 235
  • [6] Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
    Amass, Leslie
    Li, Huihua
    Gundapaneni, Balarama K.
    Schwartz, Jeffrey H.
    Keohane, Denis J.
    ORPHANET JOURNAL OF RARE DISEASES, 2018, 13
  • [7] Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
    Leslie Amass
    Huihua Li
    Balarama K. Gundapaneni
    Jeffrey H. Schwartz
    Denis J. Keohane
    Orphanet Journal of Rare Diseases, 13
  • [8] NNI-351, A First-in-Class Candidate for Disease-modifying ADHD Treatment
    Kelleher-Andersson, Judith
    Wells, Matthew
    NEUROTHERAPEUTICS, 2018, 15 (03) : 830 - 830
  • [9] The effectiveness and value of disease-modifying therapies for transthyretin amyloid cardiomyopathy
    Nikitin, Dmitriy
    Wasfy, Jason H.
    Winn, Aaron N.
    Raymond, Finn
    Shah, Kanya K.
    Kim, Sodam
    Touchette, Daniel R.
    Lee, Woojung
    Richardson, Marina
    Rind, David M.
    Pearson, Steven D.
    Agboola, Foluso
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (03): : 323 - 328
  • [10] Correlation of clinical outcomes and disease burden in patients with transthyretin (TTR) amyloid polyneuropathy:: study Fx-005, a landmark clinical trial of Fx-1006A, a novel small molecule TTR stabiliser
    Coelho, T.
    Waddington-Cruz, M.
    Plante-Bordeneuve, V.
    Cros, D.
    Grogan, D. Roy
    Packman, J.
    JOURNAL OF NEUROLOGY, 2008, 255 : 78 - 78
12345